Pravafenix
·
- Prescription status not stated
- Heart, blood pressure and circulation
- Active substance
- Fenofibrate;pravastatin
- Made by
- Laboratoires SMB S.A.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Pravafenix is indicated as an adjunct to diet and other non-pharmacological treatment (e.g. exercise, weight reduction) for the treatment of mixed hyperlipidaemia in adult patients at high cardiovascular risk to reduce triglycerides and increase HDL C when LDL C levels are adequately controlled while on a treatment with pravastatin 40 mg monotherapy or on another moderate-intensity statin regimen.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Laboratoires SMB S.A. |
|---|---|
| Active substance | Fenofibrate;pravastatin |
| Used in | Heart, blood pressure and circulation |
| Classification | C10BA03 · Heart, blood pressure and circulation |
| Authorised on | 2011-04-14 |
| Last updated by the regulator | 2025-01-17 |
| EMA product number | EMEA/H/C/001243 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).